Vanta Bioscience (540729) Stock Overview
Operates as a preclinical contract research organization in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
540729 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Vanta Bioscience Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹23.05 |
| 52 Week High | ₹56.00 |
| 52 Week Low | ₹19.08 |
| Beta | 0.83 |
| 1 Month Change | 4.63% |
| 3 Month Change | n/a |
| 1 Year Change | -52.43% |
| 3 Year Change | -68.42% |
| 5 Year Change | -87.56% |
| Change since IPO | -54.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| 540729 | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | -5.0% | 1.8% | 1.5% |
| 1Y | -52.4% | -0.4% | -4.7% |
Return vs Industry: 540729 underperformed the Indian Life Sciences industry which returned -3.2% over the past year.
Return vs Market: 540729 underperformed the Indian Market which returned -6% over the past year.
Price Volatility
| 540729 volatility | |
|---|---|
| 540729 Average Weekly Movement | 9.3% |
| Life Sciences Industry Average Movement | 5.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 8.3% |
| 10% least volatile stocks in IN Market | 3.2% |
Stable Share Price: 540729's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: 540729's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 48 | Dopesh Mulakala | www.vantabio.com |
Vanta Bioscience Limited, together with its subsidiaries, operates as a preclinical contract research organization in India. It offers a range of services in method development, validation, impurity profiling, impurity isolation, characterization, certification and evaluation, mammalian and genetic toxicology, drug metabolism, pharmacokinetics, and bio-analysis during the preclinical stage of drug development. The company also provides testing services for agrochemicals and chemicals, such as physico-chemical testing; sub-acute, sub-chronic, and chronic; toxicokinetics assessment, CoA and dose formulation analysis, 5 batch analysis, and studies on behavior in water, soil and air, bioaccumulation, as well as acute 6 pack, carcinogenicity, genetic toxicity, DART, eco-toxicity, and alternative to animal studies.
Vanta Bioscience Limited Fundamentals Summary
| 540729 fundamental statistics | |
|---|---|
| Market cap | ₹145.49m |
| Earnings (TTM) | -₹47.75m |
| Revenue (TTM) | ₹19.64m |
Is 540729 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 540729 income statement (TTM) | |
|---|---|
| Revenue | ₹19.64m |
| Cost of Revenue | ₹13.35m |
| Gross Profit | ₹6.29m |
| Other Expenses | ₹54.04m |
| Earnings | -₹47.75m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.56 |
| Gross Margin | 32.01% |
| Net Profit Margin | -243.17% |
| Debt/Equity Ratio | 1,852.4% |
How did 540729 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 11:53 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vanta Bioscience Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.